<div class="infobox infobox-gene">
| Property | Value |
|----------|-------|
| Gene Symbol | STING (TMEM173) |
| Full Name | Stimulator of Interferon Genes |
| Chromosomal Location | 5q31.2 |
| NCBI Gene ID | 340061 |
| OMIM ID | 612374 |
| Ensembl ID | ENSG00000184584 |
| UniProt ID | Q86WV1 |
| Encoded Protein | STING protein (379 aa) |
| Associated Diseases | Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease |
</div>
STING (Stimulator of Interferon Genes), also known as TMEM173, is a transmembrane protein that serves as the central signaling hub for the cGAS-STING pathway, one of the most important innate immune sensing mechanisms in eukaryotic cells. This pathway detects cytosolic DNA and triggers type I interferon responses, inflammatory cytokine production, and autophagy—responses that are protective against viral and bacterial pathogens but become pathological when chronically activated in the brain.
The cGAS-STING pathway has emerged as a critical mechanism in neurodegenerative disease pathogenesis. Since the initial discoveries linking this pathway to Alzheimer's disease in 2019-2020, a rapidly growing body of evidence implicates chronic STING activation as a major driver of neuroinflammation, microglial senescence, and neuronal dysfunction across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD) [@xie2023][@sliter2023][@guo2022][@mathur2021].
<div class="infobox infobox-gene">
| Property | Value |
|----------|-------|
| Gene Symbol | STING (TMEM173) |
| Full Name | Stimulator of Interferon Genes |
| Chromosomal Location | 5q31.2 |
| NCBI Gene ID | 340061 |
| OMIM ID | 612374 |
| Ensembl ID | ENSG00000184584 |
| UniProt ID | Q86WV1 |
| Encoded Protein | STING protein (379 aa) |
| Associated Diseases | Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease |
</div>
STING (Stimulator of Interferon Genes), also known as TMEM173, is a transmembrane protein that serves as the central signaling hub for the cGAS-STING pathway, one of the most important innate immune sensing mechanisms in eukaryotic cells. This pathway detects cytosolic DNA and triggers type I interferon responses, inflammatory cytokine production, and autophagy—responses that are protective against viral and bacterial pathogens but become pathological when chronically activated in the brain.
The cGAS-STING pathway has emerged as a critical mechanism in neurodegenerative disease pathogenesis. Since the initial discoveries linking this pathway to Alzheimer's disease in 2019-2020, a rapidly growing body of evidence implicates chronic STING activation as a major driver of neuroinflammation, microglial senescence, and neuronal dysfunction across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD) [@xie2023][@sliter2023][@guo2022][@mathur2021].
The TMEM173 gene spans approximately 37 kb on the forward strand of chromosome 5q31.2 and consists of 6 exons encoding a 379-amino acid transmembrane protein. STING is composed of several functional domains:
The canonical activation sequence is:
Under normal physiological conditions, STING-mediated signaling serves essential protective functions:
STING also participates in cellular quality control:
The cGAS-STING pathway is now recognized as a central driver of neuroinflammation in AD. Multiple studies have demonstrated that:
Aβ-induced STING activation: Amyloid-beta plaques and oligomers directly activate the cGAS-STING pathway in microglia and neurons. Aβ fibrils trigger mitochondrial damage, releasing mitochondrial DNA (mtDNA) into the cytosol where it is detected by cGAS [@xie2023].
Microglial senescence: AD-linked risk alleles (including TREM2 and APOE variants) elevate microglial cGAS activity, promoting a senescence-associated secretory phenotype (SASP) that drives neurodegeneration in tauopathy models [@czirr2024].
Type I interferon pathology: Chronic elevation of brain-derived beta-interferon correlates with cognitive impairment in AD patients. IL-6 deficiency reduces neuroinflammation by inhibiting the STAT3-cGAS-STING pathway in AD mouse models [@goldberg2024].
Therapeutic targeting: Blockade of STING activation alleviates microglial dysfunction and reduces multiple AD pathologies including amyloid plaques, tau tangles, and synaptic loss [@meng2024]. Several pharmaceutical companies are developing STING inhibitors for AD therapy.
Key mechanisms in AD:
Alpha-synuclein pathology: Alpha-synuclein aggregates activate the cGAS-STING pathway in microglia and neurons. The Sliter et al. (2023) study demonstrated that cGAS-STING is required for alpha-synuclein-induced neuroinflammation and dopaminergic neuron loss [@sliter2023].
Mitochondrial dysfunction: PD-associated mutations in PINK1, Parkin, and LRRK2 impair mitophagy, leading to accumulation of damaged mitochondria that release mtDNA into the cytosol, activating cGAS-STING.
Dopaminergic neuron vulnerability: STING-dependent inflammation specifically targets dopaminergic neurons in the substantia nigra, consistent with the pattern of neuron loss in PD.
Therapeutic implications: STING inhibitors may protect dopaminergic neurons from alpha-synuclein toxicity. The pathway represents a novel therapeutic target for disease modification in PD.
TDP-43 pathology: TDP-43 protein aggregates, the hallmark of ALS, activate the cGAS-STING pathway. Motor neurons with TDP-43 pathology show chronic STING activation leading to neuroinflammation and motor neuron death [@guo2022].
Astrocyte activation: STING mediates non-cell autonomous neurodegeneration through astrocyte activation. ALS astrocytes release inflammatory cytokines that kill motor neurons, and this effect is partially STING-dependent.
Genetic links: GWAS studies have identified STING variants associated with ALS risk, suggesting genetic susceptibility to STING dysregulation.
C9orf72 connection: The most common genetic cause of ALS (C9orf72 repeat expansion) may intersect with STING signaling, as C9orf72 normally regulates lysosomal trafficking and autophagy.
Mutant huntingtin effects: Mutant huntingtin protein activates the cGAS-STING pathway through multiple mechanisms [@mathur2021]:
STING exhibits broad expression across neural cell types:
Several classes of STING inhibitors are in development:
| Compound | Company | Stage | Notes |
|----------|---------|-------|-------|
| C-176 | Calthera | Preclinical | Covalent inhibitor of STING |
| H-151 | InvivoChem | Preclinical | Selective STING antagonist |
| Astibatin | BMS | Clinical trials | Originally developed for autoimmunity |
Existing drugs with STING-modulating properties:
STING activation markers in cerebrospinal fluid (CSF) may serve as biomarkers:
The cGAS-STING pathway drives neurodegeneration through multiple interconnected mechanisms:
1. Mitochondrial Dysfunction Cascade
The pathological sequence begins with mitochondrial damage induced by disease-relevant proteins:
2. Microglial Activation and SASP
STING activation in microglia induces a senescence-associated secretory phenotype (SASP):
3. Type I Interferon Toxicity
Chronic IFN-β production has direct neurotoxic effects:
The cGAS-STING pathway may explain the characteristic spread of pathology in neurodegenerative diseases:
In AD: Pathology spreads along limbic and default mode networks, consistent with a prion-like spread of tau and Aβ. STING activation in connected brain regions may amplify this spread through intercellular signaling.
In PD: Alpha-synuclein pathology spreads from the olfactory bulb and gut to the substantia nigra. STING activation in the gut-brain axis and in olfactory bulb may initiate and propagate pathology.
| Strategy | Mechanism | Status | Challenges |
|----------|-----------|--------|------------|
| Covalent inhibitors | Form adducts with STING cysteine residues | Preclinical | Specificity, off-target effects |
| Allosteric modulators | Bind STING domains to prevent conformational change | Preclinical | Brain penetration |
| cGAMP analogs | Compete for cGAMP binding site | Preclinical | Stability, delivery |
| TBK1 inhibitors | Block downstream kinase activation | Clinical (cancer) | Need for CNS penetration |
Since STING activation leads to multiple downstream pathways, alternative strategies include:
STING pathway activation produces measurable signatures:
CSF biomarkers:
STING pathway activity may predict disease progression:
Several mouse models reproduce STING pathway activation:
Preclinical studies demonstrate:
Several trials target the STING pathway:
The following diagram shows key molecular relationships for STING Gene based on knowledge graph edges:
The following diagram shows the key molecular relationships involving STING Gene discovered through SciDEX knowledge graph analysis: